Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The meningococcal ABCYW vaccine (specifically Sanofi's SP0230) is a pentavalent vaccine candidate designed to provide broad protection against invasive meningococcal disease (IMD) caused by *Neisseria meningitidis* serogroups A, B, C, W, and Y. Developed by Sanofi Pasteur, the vaccine combines the capsular polysaccharide conjugates from a quadrivalent MenACWY vaccine (such as MenQuadfi) with recombinant protein antigens targeting serogroup B (such as factor H binding protein). By covering all five major pathogenic serogroups in a single immunization series, it aims to simplify vaccination schedules and increase coverage against MenB, which is often administered separately from the quadrivalent conjugate vaccines. The vaccine is currently in Phase 2 clinical development for use in infants, toddlers, and children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meningococcal ABCYW vaccine (Sanofi).